Video

Treatment Options for Advanced HCC in the Second-Line and Beyond

Brief but comprehensive insight to the cornerstone second-line treatment options in the setting of recurrent advanced hepatocellular carcinoma.

Transcript:

Josep Llovet, MD: It’s about time to move to second-line [therapy]. I have some slides that I will mention very briefly. Regorafenib showed superiority against placebo in second line in patients who tolerated or progressed to sorafenib. This was a trial that showed a hazard ratio of 0.63 and a median overall survival of 10.6 months for regorafenib This established that it works in group analyses.

Cabozantinib is a multikinase inhibitor with a uniqueness that’s blocking MET signaling. It showed superiority vs placebo, with a median survival of 10.2 months vs around 8 months. In the subgroup analysis, cabozantinib shows more efficacy in patients with extrahepatic spread, macrovascular invasion, and hepatitis B virus infection.

Finally, ramucirumab in the REACH trial was negative. In the subgroup analysis, for patients with AFP [alpha-fetoprotein] of more than 400 ng/mL, the drug was efficacious. In the second trial, REACH-2, [median survival was] 8.5 months; the control arm was 7.3. But in the meta-analysis, that probably captures better population in the second line with an AFP of more than 400 ng/mL—40% of patients in the second line and have of AFP more than 400 ng/mL. The median survival for placebo is 5 months and around 8 months for ramucirumab.

In terms of adverse events, regorafenib has grade 3/4 adverse events in 50% of the population in the second line. Patients who do not tolerate sorafenib have been excluded in the trial. For CELESTIAL, the trial didn’t really publish treatment-related adverse events, but it’s estimated to be 55% or 60%.

Transcript edited for clarity.

Related Videos
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center
Suneel Kamath, MD
Suneel Kamath, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Olivia Aranha, MD, PhD
Michael Iglesia, MD, PhD
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Arndt Vogel, MD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Haeseong Park, MD, MPH